Roche Drops Hemophilia A Candidate, Prepares for the Impacts of IRA

Roche is discontinuing the development of the mid-stage gene therapy candidate RG6358, or SPK-8016, which was previously being assessed as a treatment for hemophilia A patients with inhibitors to factor VIII, the company announced Thursday in its second-quarter earnings report.